# NOBO Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nobo-medicine

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.nobomedicine.com/
- Total disclosed funding: $20M
- Latest round: Series C (Jun 13, 2025)
- Investors on record: 9

## About

NOBO Medicine, Inc., based in South Korea, specializes in developing innovative therapeutics through biomarker-driven methodologies, focusing on precision medicine solutions for oncology and chronic diseases.Founded in 2017 and headquartered in Seoul, South Korea, NOBO Medicine, Inc. develops therapeutics based on precision medicine approaches. The company has completed one funding deal, securing KRW 5 billion from STIC Ventures in June 2025, representing the total amount raised. NOBO Medicine focuses on developing innovative therapeutics grounded in biomarker-driven methodologies. Their primary offerings emphasize precision medicine solutions that identify optimal patient populations for novel drug candidates in clinical development. By utilizing clinical information and biomarker data, NOBO aims to address unmet medical needs in oncology and chronic diseases. The company targets healthcare providers, research institutions, and pharmaceutical companies, particularly in Asian markets with a concentration in South Korea.NOBO Medicine's revenue model is structured around partnerships with healthcare institutions and pharmaceutical companies for its drug development services. The company engages in B2B transactions, collaborating with research organizations and oncologists to provide precision medicine solutions. Revenue streams are anticipated from contractual agreements that include milestone payments for successful drug candidates and collaboration fees tied to research initiatives. Their flagship products, currently under development, are expected to integrate into existing therapeutic frameworks, enhancing treatment capabilities and meeting specific patient needs.In June 2025, NOBO Medicine, Inc. raised KRW 5 billion in venture funding from STIC Ventures. This funding will support the continued development of their innovative drug candidates and facilitate expansion into new markets, particularly targeting additional regions in Asia. The company plans to launch new products based on ongoing research efforts and aims for a significant market presence by 2026.

## Funding rounds

- Series C, Jun 13, 2025, $20M — Korea Investment & Securities, Industrial Bank of Korea, Partners Investment, STIC Ventures, Stassets Investment, Curocell Inc., Stonebridge Ventures, Yuhan Corporation, Dongkuk Investment

## Investors

- Korea Investment & Securities (https://capitalatlas.ai/funds/korea-investment-securities) — Series C
- Industrial Bank of Korea — Series C
- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Series C
- STIC Ventures (https://capitalatlas.ai/funds/stic-ventures) — Series C
- Stassets Investment (https://capitalatlas.ai/funds/stassets-investment) — Series C
- Curocell Inc. — Series C
- Stonebridge Ventures — Series C
- Yuhan Corporation — Series C
- Dongkuk Investment (https://capitalatlas.ai/funds/dongkuk-investment) — Series C